To the best of our knowledge, this is the first work that shows downregulation or inhibition of Nav1.6 could affect the Aβ production; therefore, Nav1.6 may become a novel therapeutic target to slow down the progression of AD. The gene discussed is SCN8A; the disease is Alzheimer disease.